Cydan is a collaborative team of scientists and entrepreneurs experienced in orphan drug development.
Cydan is the first orphan drug accelerator dedicated to advancing therapies that improve the lives of patients with rare genetic diseases. We are doing this because there are more than 7,000 rare diseases, with approximately 400 approved treatments. That’s not good enough.
We are a collaborative team of scientists and entrepreneurs with comprehensive expertise in drug and business development. We conceived of Cydan in 2012 and launched the company in 2013, assembling a team of drug hunters with extensive drug discovery, clinical development and business development experience. In early 2015, we launched our first new company – Vtesse – which is developing drugs for Niemann-Pick Disease Type C (NPC) and other rare, severe diseases with great unmet need. One year after launching Vtesse, we created Imara to develop IMR-687, a novel treatment for people living with sickle cell disease. In 2016 and 2017, we anticipate launching several more new companies.
Cydan starts with a compelling scientific idea or promising drug candidate from collaborators in academia and industry, and then efficiently advances therapies through pre-clinical R&D to enable the establishment of an independent company to accelerate such therapy through clinical, regulatory and commercial development and ultimately to patients.
Cydan’s experience creating new companies and access to capital is a key advantage. We are financed by leading life sciences investors, New Enterprise Associates, Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments.
The Cydan accelerator is based in Technology Square in Cambridge, MA.